The trial was aimed at studying the effects of the modulator of bone metabolism - strontium ranelate on the parameters of cardiovascular remodeling in women with postmenopausal osteoporosis (OP) and arterial hypertension (AH). This effect includes the results of study of strontium ranelate in 48 women with postmenopausal osteoporosis AH 1-2 degrees and moderate or high cardiovascular risk. During 36 weeks 25 patients, in addition to antihypertensive therapy and calcium supplementation received strontium ranelate (Bivalos) 2 g / day. Bone mineral density (BMD) was evaluated by dual energy X-ray absorptiometry. The effect of strontium ranelate treatment on the thickness of the intima-media of the carotid artery (IMT) by the method of duplex scanning on structural and functional parameters of the heart by echocardiography also evaluated. Adding of strontium ranelate to the antihypertensive treatment and calcium supplementation in women with postmenopausal OP and AH has a positive effect on central hemodynamics, cardiovascular remodeling and diastolic filling.

Primary hyperparathyroidism (PHPT) is a common disorder often associated with reduced bone mineral density (BMD) and osteoporosis. The main goal in treating patients who refuse surgery is the correction of bone complications.
The aim of this study is to evaluate safety and efficacy of alendronate treatment in patients with PHPT and osteoporosis. Eligible patients were postmenopausal women suffering from PHPT who did not meet surgical guidelines or ignored surgery due to different reasons. 55 osteoporotic or osteopenic women received alendronate 70 mg weekly and 43 were leaved under medical observation for the reasons of not being osteoporotic or financial unable to comply with treatment/
Results: After 2 years of treatment alendronate group showed statistically significant gain in BMD at L24 +4,0±4,2%, Neck +2,2±4,4%„ TH +2,3±4,5%. At the same time observational group showed decrease in BMD at L24 -4,2±4,0%, TH -3,5±3,8%, R33% -4,0±6,5%, [95% CI -7,6; -0,4]. On the whole BMD dynamics in groups differed at the following sites: L2 (p=0,00004), Neck (p=0,005), TH (p=0,001), R33% (p=0,006). '
Alendronate intake was accompanied by serum Ca decrease (at 1 year point -4,3±5,4%, p=0,00005, at 2 year -2,7±6,4%, p=0,04), 24 hours'Ca excretion decrease from (Me) 8,5 to 6,3 mmol/day at 1 year point, (p=0,007) without PTH elevation. As well as CTx fell at Me: 66% at 1 year and at 60% at 2 year point and OK at 39% and at 27%, correspondingly, p<0,01. In the observation group PTH, serum Ca were stable, 24 hours 'Ca excretion increased from 7,0 to 7,7 at 2 year, p=0,003, as well as CTx level that increased 53%, p=0,01 at 2 years.
Conclusions: alendronate treatment in postmenopausal women improves BMD in trabecular bone sites and prevents BMD decrease in cortical sites. At least 2 years of therapy is needed to get the significant increase BMD in cortical bone . All patients should be under medical control for timely revelation of disease progression.

Primary hyperparathyroidism (PHPT) is a common endocrine disorder that affects bones, urinary tract, cardiovascular system, gastrointestinal tract, and another organs and tissues. The most cases of PHPT are mild forms and those patients have nonspecific symptoms, which require careful diagnostic considerations and choice of treatment.
There is not enough data about prevalence of PHPT, especially it's mild forms, in Russian Federation, and future epidemiological research needs to be done.
Present literature review includes information about etiology, pathogenesis, clinical findings, diagnostic and differential diagnostic, indication for surgery and medical treatment of PHPT. The review is based on data of studies from the different countries and few studies from Endocrine science center.

Despite the relatively low incidence of acromegaly (60-70 cases per I million inhabitants), this disease has a special place among the heterogeneous group of diseases that lead to the defeat of the locomotor apparatus. The slow growth of the clinical manifestations of acromegaly and as a consequence, late diagnosis, the cause of early disability and premature death of patients. In order to improve the quality of life and social adaptation of patients to date is an obvious need to identify groups of patients with acromegaly, requiring additional therapy for osteoporosis and osteoarthritis. We performed the search in bibliographic bases MEDLINE and Cochrane Collaboration from 2000 on 2009. Key words were the following: acromegaly, acromegaly and arthropathy, osteoporosis and acromegaly, the bone mineral density and acromegaly, fractures and acromegaly. In this article the data about role of risk factors for the defeat ofosteoarticular apparatus, the dynamics of the articular syndrome and the state of bone tissue in acromegaly.

Osteoarthritis is the most common disorders of the locomotor system. This is multifaktor disorder and the inflammation in the bones and cartilage, synovial envelope and subhondral bone play the important role in the pathogenesis of osteoarthritis. The main symptom-modified drugs are glikozamin sulfate and chondroitine sulfate, which have a high degree of evidence. These agents not only suppress pain and normalize function affected joints but also slowed progression of osteoarthritis, normalize and stabilize the structural changes in gyaline cartilage, warn changes in noninvolved joint. Theraflex is combined and includes both basic structural modifier cartilage. It has all the properties that are called chondroprotektive drugs.

Osteoporosis is one of the most socially significant chronic noninfectious diseases. This is due to its high prevalence and medical, social and economic consequences from osteoporotic bone fractures. The problem of osteoporosis is intensively studied in Russia for the past 15 years. Taking into account the peculiarities of the osteoporotic process (gradual, protracted, oligosymptomatic beginning, multifactorial origin, need for prolonged treatment to achieve effectiveness, wide range of drug treatment options etc.) and remaining lack of knowledge and experience of practitioners in view of the swift progress in osteoporosis research, we consider the importance of unity in approach to diagnosis, prophylaxis and treatment of osteoporosis for doctors of all specialities. These prompted Russian experts to develop the first Russian Clinical Recommendations for osteoporosis that were published in 2005 and reviewed in 2009.